Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin L Sos

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Cancer Research|June 8, 2023
Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung CancerNina Müller, Carina Lorenz, Jenny Ostendorp, et al.
Molecular Oncology|May 22, 2026
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancerJun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2015
Discovery and functional characterization of a neomorphic PTEN mutationHelio A Costa, Michael G Leitner, Martin L Sos, et al.
EMBO Reports|July 1, 2026
AURORA A interacts with DICER and SETD2 to promote S-phase progressionJuliane Müller, Tina Daunke, Nicola Berner, et al.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Cancer Research|April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
Science Translational Medicine|July 8, 2011
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingJuliann Chmielecki, Jasmine Foo, Geoffrey R Oxnard, et al.
Nature Communications|April 7, 2021
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesChristina M Bebber, Emily S Thomas, Jenny Stroh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsDennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Cancer Research|June 8, 2023
Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung CancerNina Müller, Carina Lorenz, Jenny Ostendorp, et al.
Molecular Oncology|May 22, 2026
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancerJun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2015
Discovery and functional characterization of a neomorphic PTEN mutationHelio A Costa, Michael G Leitner, Martin L Sos, et al.
EMBO Reports|July 1, 2026
AURORA A interacts with DICER and SETD2 to promote S-phase progressionJuliane Müller, Tina Daunke, Nicola Berner, et al.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Cancer Research|April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
Science Translational Medicine|July 8, 2011
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingJuliann Chmielecki, Jasmine Foo, Geoffrey R Oxnard, et al.
Nature Communications|April 7, 2021
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesChristina M Bebber, Emily S Thomas, Jenny Stroh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsDennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Pageof 6